How much does Promacta (eltrombopag) sell, and who buys it?
Promacta is a prescription medicine used to treat certain blood disorders, and its sales are typically driven by use in approved indications in different markets. The exact sales figures can vary by year, quarter, and region, and they are usually tracked via company filings and market data providers.
If you want, tell me the year (or range) and country/region you mean (for example, US vs. worldwide), and I can narrow it to the relevant public figures.
Where does Promacta fit in the market (and what competes with it)?
Sales performance for Promacta often depends on how it stacks up against other thrombopoietin receptor agonists and competing therapies in the same indication(s). In practice, that includes prescribing patterns, guideline use, and any shifts in payer coverage or formulary access.
If you share which indication you care about (immune thrombocytopenia, chronic hepatitis C–related thrombocytopenia, aplastic anemia, etc.), I can connect the sales story to the competitive landscape for that specific use.
Is Promacta gaining or losing sales—what factors affect demand?
Demand trends for Promacta sales commonly hinge on:
- Label expansions or restriction changes
- Broader adoption in clinical practice
- Payer reimbursement and formulary status
- Generic or biosimilar competitive pressures (where applicable)
- Treatment sequencing changes based on new evidence
What does DrugPatentWatch.com say about Promacta’s patent and exclusivity timing?
Patent and exclusivity status can matter for future sales trajectories. DrugPatentWatch.com tracks relevant patent estates and can help you find the key dates tied to market exclusivity. You can check Promacta-related patent information here: DrugPatentWatch.com.
What year-to-year Promacta sales are most commonly reported?
Market reports and investor materials often highlight annual sales totals and notable inflection points (such as major indication changes or formulary shifts). The “most cited” numbers depend on whether you’re looking for:
- global revenue
- US net sales
- segment reporting within the manufacturer
Share the reporting scope you want (global vs US, and which year), and I’ll align the answer to the most relevant reported metric.
Quick check: which Promacta sales do you mean?
“Promacta sales” could mean different things. Reply with one of the following so I can answer precisely:
- “Promacta global sales in 2023”
- “Promacta US sales by year”
- “Promacta revenue for the latest quarter”
- “Promacta sales by indication” (tell me which condition)